Graham Capital Management L.P. Decreases Stock Position in Insulet Corporation $PODD

Key Points

• Graham Capital Management L.P. reduced its stake in Insulet Corporation by 41.3%, now holding 6,391 shares valued at approximately $1.68 million.
• Other institutional investors, including Larson Financial Group and Golden State Wealth Management, significantly increased their positions, with Larson boosting their stake by 426.3%.
• Analysts remain optimistic about Insulet, with a consensus rating of "Moderate Buy" and a price target averaging $332.71, reflecting confidence in its growth potential.

Graham Capital Management L.P. cut its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 41.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,391 shares of the medical instruments supplier's stock after selling 4,502 shares during the quarter. Graham Capital Management L.P.'s holdings in Insulet were worth $1,678,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT purchased a new stake in Insulet during the first quarter worth about $26,000. Larson Financial Group LLC boosted its holdings in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 81 shares in the last quarter. SouthState Corp boosted its holdings in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 76 shares in the last quarter. Ramirez Asset Management Inc. purchased a new stake in Insulet during the first quarter worth about $53,000. Finally, Golden State Wealth Management LLC boosted its holdings in Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after buying an additional 177 shares in the last quarter.

Wall Street Analyst Weigh In

PODD has been the subject of a number of research reports. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. The Goldman Sachs Group assumed coverage on shares of Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective for the company. Finally, Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Trading Up 0.6%

PODD stock traded up $1.96 on Friday, hitting $348.43. 498,473 shares of the company were exchanged, compared to its average volume of 584,368. Insulet Corporation has a twelve month low of $211.27 and a twelve month high of $350.00. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The business's fifty day moving average is $307.55 and its two-hundred day moving average is $289.86. The stock has a market capitalization of $24.53 billion, a price-to-earnings ratio of 105.91, a price-to-earnings-growth ratio of 2.92 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the prior year, the business posted $0.55 earnings per share. Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.